Vivo Bio Tech Limited (511509) Fair Value & Analysis
Healthcare · IN · Market cap ₹639M
Fair value as of: Jul 5, 2026
From 6 valuation models · updated today
Fair value updated Jul 5, 2026 — revised from ₹91.59 to ₹43.66 (−52.3%) since Jul 4, 2026. Share price −0.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹21.05 – ₹41.18 · fair‑value band ₹26.65 – ₹60.67 · the ₹23.62 price screens below the ₹43.66 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vivo Bio Tech Limited (511509) currently trades at ₹23.62, while our model-based Fair Value estimate is ₹43.66 — implying the stock looks roughly 84.8% undervalued today. We read business quality at 25/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Vivo Bio Tech Limited generated revenue of ₹512M at a net margin of 8.2%. Revenue declined 31.4% year over year. Net debt stands at ₹659M. The stock trades on a trailing P/E of 12.2. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹26.65 (bear case) to ₹60.67 (bull case); at ₹23.62, the current price sits below that range. The share trades about 46% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at 85%, 511509 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vitro, in vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxico kinetic studies, genotoxicity screening, analytical services, etc. It also supplies SPF lab animals. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Vivo Bio Tech Limited reported revenue of ₹533M in FY2026 versus ₹514M in FY2022, a compound +0.9%/yr. Reported net income was −₹17.1M in FY2026.
Is 511509 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vivo Bio Tech Limited (511509) undervalued?
What is the fair value of 511509?
What is the quality score of 511509?
What is the revenue of Vivo Bio Tech Limited (511509)?
What is the net profit margin of 511509?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.